GENFLOW BIOSCIENCES PLC(GENF.UK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

GENF.UK GENFLOW BIOSCIENCES PLC

Trading 01-05 08:50:00 GMT Delay

1.95

+0.00

0.00%

High1.95	Low1.95	Vol0.00
Open1.95	D1 Closing1.95	Amplitude0.00%
Mkt Cap962.42M	Tradable Cap409.19M	Total Shares493.55M
T/O0.00	T/O Rate0.00%	Tradable Shares209.84M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GENF.UK","market":"UK","secType":"STK","nameCN":"GENFLOW BIOSCIENCES PLC","latestPrice":1.95,"timestamp":1767603000000,"preClose":1.95,"halted":0,"volume":0,"delay":15,"nameEN":"GENFLOW BIOSCIENCES PLC","floatShares":209842025,"shares":493547942,"eps":-0.48979999999999996,"marketStatus":"Trading","change":0,"latestTime":"01-05 08:50:00 GMT Delay","open":1.95,"high":1.95,"low":1.95,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.48979999999999996,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1767630600000},"marketStatusCode":2,"adr":0,"exchange":"LSE","adjPreClose":1.95,"openAndCloseTimeList":[[1767600000000,1767630600000]],"volumeRatio":0,"tradeCurrency":"GBX","tradeService":"SETSqx","exchangeMarketSize":30000},"requestUrl":"/m/hq/s/GENF.UK/wiki","defaultTab":"wiki","newsList":[{"id":"2591606520","title":"Genflow Biosciences Completes Dosing in Canine Gene Therapy Trial with No Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2591606520","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591606520?lang=en_us&edition=fundamental","pubTime":"2025-12-16 15:00","pubTimestamp":1765868445,"startTime":"0","endTime":"0","summary":"Genflow Biosciences plc has announced the completion of the dosing phase in its ongoing clinical trial evaluating a SIRT6-based gene therapy in dogs. According to the company, all enrolled dogs have received the full administration of the investigational therapy, with no adverse events or side effects reported during this phase. The study is being conducted as a blinded clinical trial, and efficacy outcomes have not yet been assessed. Genflow expects to present initial efficacy data, including blood analyses and muscle biopsies, in mid-to-late January 2026, with a second assessment planned at the six-month timepoint. The company also indicated plans to explore early-stage licensing opportunities following analysis of the efficacy data.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL6jw252:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK5083","GENF.UK"],"gpt_icon":0},{"id":"2590567102","title":"Genflow Biosciences to Attend J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2590567102","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590567102?lang=en_us&edition=fundamental","pubTime":"2025-12-11 15:01","pubTimestamp":1765436468,"startTime":"0","endTime":"0","summary":"Genflow Biosciences plc will attend the 44th Annual J.P. Morgan Healthcare Conference, taking place from January 12-15, 2026, at the Westin St. Francis in San Francisco, California. The company will use this opportunity to engage with potential partners, institutional investors, and pharmaceutical companies as it advances its gene-therapy pipeline targeting the SIRT6 longevity pathway.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genflow Biosciences plc published the original content used to generate this news brief via ACCESS Newswire  on December 11, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL77p6Gd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENF.UK","BK5083"],"gpt_icon":0},{"id":"2579443471","title":"Genflow Biosciences Announces Updated Total Issued Shares and Voting Rights","url":"https://stock-news.laohu8.com/highlight/detail?id=2579443471","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579443471?lang=en_us&edition=fundamental","pubTime":"2025-10-31 15:00","pubTimestamp":1761894056,"startTime":"0","endTime":"0","summary":"Genflow Biosciences plc has announced that, as of 31 October 2025, its total issued share capital consists of 493,547,942 Ordinary Shares, with none held in treasury. This means the total number of voting rights in the company is also 493,547,942. Shareholders can use this figure to determine disclosure obligations under the Financial Conduct Authority's rules.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genflow Biosciences plc published the original content used to generate this news brief via ACCESS Newswire  on October 31, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL4ft8hk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENF.UK","BK5083"],"gpt_icon":0},{"id":"2577695337","title":"BRIEF-Genflow Biosciences PLC - Announces Second European Patent Application Published","url":"https://stock-news.laohu8.com/highlight/detail?id=2577695337","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577695337?lang=en_us&edition=fundamental","pubTime":"2025-10-22 14:15","pubTimestamp":1761113753,"startTime":"0","endTime":"0","summary":"BRIEF-Genflow Biosciences PLC - Announces Second European Patent Application PublishedGenflow Biosciences PLC GENF.L:GENFLOW BIOSCIENCES PLC - ANNOUNCES SECOND EUROPEAN PATENT APPLICATION PUBLISHEDGEN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nFWN3W2256:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENF.UK","BK5083"],"gpt_icon":0},{"id":"2577337887","title":"Genflow Biosciences Plc - Publication Enables Genflow to Claim Retroactive Damages Under Epc","url":"https://stock-news.laohu8.com/highlight/detail?id=2577337887","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577337887?lang=en_us&edition=fundamental","pubTime":"2025-10-22 14:08","pubTimestamp":1761113323,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nFWN3W2256:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK5083","GENF.UK"],"gpt_icon":0},{"id":"2577332284","title":"Genflow Biosciences Publishes European Patent Application for SIRT6 Variant Targeting NASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2577332284","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577332284?lang=en_us&edition=fundamental","pubTime":"2025-10-22 14:00","pubTimestamp":1761112821,"startTime":"0","endTime":"0","summary":"Genflow Biosciences plc has announced the publication of its second European patent application for a SIRT6 gene variant targeting non-alcoholic steatohepatitis . The patent, now public and provisionally enforceable in Europe, represents a major step in expanding Genflow's intellectual property portfolio in the fields of longevity and metabolic diseases. The company emphasized that this development enhances its platform for future clinical programs and partnership opportunities. No specific presentation of scientific research results was mentioned in the announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genflow Biosciences plc published the original content used to generate this news brief via ACCESS Newswire  on October 22,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nNDL2yGnR8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENF.UK","BK5083"],"gpt_icon":0},{"id":"2576304880","title":"Genflow Biosciences’ SIRT6 Variant Patent Claims Recognized as Patentable by European Patent Office","url":"https://stock-news.laohu8.com/highlight/detail?id=2576304880","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576304880?lang=en_us&edition=fundamental","pubTime":"2025-10-20 14:00","pubTimestamp":1760940015,"startTime":"0","endTime":"0","summary":"Genflow Biosciences plc announced that the European Patent Office has recognized the patentability of claims related to its SIRT6 variant patent application . The patent application has now entered its final pre-grant phase, with provisional protection in effect across participating EPO member states. Genflow must bring the description into compliance with the claims before the European Patent Office issues an intention to grant. This development marks significant progress toward securing formal European patent protection for the company's technology.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genflow Biosciences plc published the original content used to generate this news brief via ACCESS Newswire  on October 20, 2025, and is sol","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDLbBMCpm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENF.UK","BK5083"],"gpt_icon":0},{"id":"2574914493","title":"BRIEF-Genflow Biosciences Says Repeat Administration Of SIRT6 Shows Excellent Safety & Tolerability Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2574914493","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574914493?lang=en_us&edition=fundamental","pubTime":"2025-10-10 14:27","pubTimestamp":1760077625,"startTime":"0","endTime":"0","summary":"BRIEF-Genflow Biosciences Says Repeat Administration Of SIRT6 Shows Excellent Safety & Tolerability ProfileOct 10 (Reuters) - Genflow Biosciences PLC GENF.L:GENFLOW BIOSCIENCES PLC - REPEAT ADMINISTRA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nFWN3VR0XH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENF.UK","BK5083"],"gpt_icon":0},{"id":"2574419141","title":"Genflow Biosciences Plc - Repeat Administration of Sirt6 Shows Excellent Safety and Tolerability Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2574419141","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574419141?lang=en_us&edition=fundamental","pubTime":"2025-10-10 14:07","pubTimestamp":1760076474,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nFWN3VR0XH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK5083","GENF.UK"],"gpt_icon":0},{"id":"2574141987","title":"Genflow Biosciences announces clinical trial update for SIRT6 gene therapy in aging dogs","url":"https://stock-news.laohu8.com/highlight/detail?id=2574141987","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574141987?lang=en_us&edition=fundamental","pubTime":"2025-10-10 14:00","pubTimestamp":1760076018,"startTime":"0","endTime":"0","summary":"Genflow Biosciences plc has announced an update on its Dog Aging  study, a proof-of-concept clinical trial evaluating the safety and efficacy of its proprietary SIRT6-centenarian gene therapy for age-related decline in elderly dogs. The therapy, based on a gene variant sourced from human centenarians, is designed to improve DNA repair, metabolic regulation, and resistance to age-related decline. In the ongoing randomized, controlled trial involving 28 beagles aged 10 years and older, recipients have received repeat administrations of the SIRT6 gene therapy with no ill or adverse effects observed. The study is currently in a follow-up period, which is expected to conclude in January 2026. Results have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fina","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nNDL3dgKSl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENF.UK","BK5083"],"gpt_icon":0},{"id":"2574180862","title":"Genflow Biosciences plc CEO Eric Leire Subscribes for 40 Million New Ordinary Shares in Latest Commercial Paper Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2574180862","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574180862?lang=en_us&edition=fundamental","pubTime":"2025-10-09 14:17","pubTimestamp":1759990671,"startTime":"0","endTime":"0","summary":"Genflow Biosciences plc has announced an internal dealing involving its CEO, Dr. Eric Leire. The company has raised gross proceeds of 440,000 through the allotment of 40,000,000 new ordinary shares to Dr. Leire. This transaction reflects continued support from key leadership and will provide additional capital for Genflow to pursue its near-term objectives. No commercial paper transactions were reported.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genflow Biosciences plc published the original content used to generate this news brief on October 09, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nNDL6Fbmgt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK5083","GENF.UK"],"gpt_icon":0},{"id":"2571189513","title":"Genflow Biosciences Secures Wallonia Region Grant to Advance SIRT6 Gene Therapy Program GF-1002 Toward Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2571189513","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571189513?lang=en_us&edition=fundamental","pubTime":"2025-09-30 14:00","pubTimestamp":1759212036,"startTime":"0","endTime":"0","summary":"**Genflow Biosciences plc Advances SIRT6 Platform with New Regional Grant** London, September 30, 2025 - Genflow Biosciences plc  announced in its latest half-year report that the company has received support from the Wallonia Region to advance its proprietary gene therapy candidate, GF-1002, through the next stage of development. The grant, which is currently in the finalization process, will provide non-dilutive funding to accelerate progress toward clinical readiness. Genflow did not specify whether the grant was awarded to multiple organizations or solely to Genflow Biosciences. The company anticipates sharing further updates once the grant process is complete and payment is received. This funding is expected to support Genflow's ongoing efforts in developing therapies targeting age-related diseases and enhancing healthspan in both human and veterinary applications.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDLc3Cvky:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK5083","GENF.UK"],"gpt_icon":0},{"id":"2567219391","title":"Genflow Biosciences Plc Enters Strategic CDAs with Leading Animal Health Companies to Propel Longevity Gene Therapy Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2567219391","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567219391?lang=en_us&edition=fundamental","pubTime":"2025-09-15 14:00","pubTimestamp":1757916022,"startTime":"0","endTime":"0","summary":"Genflow Biosciences Plc, the only publicly listed longevity company in Europe, has signed two Confidential Disclosure Agreements with leading animal health companies. This strategic move facilitates the exchange of data and initiates discussions on potential collaborations. The agreements are a significant step in Genflow's strategy to leverage its proprietary SIRT6-centenarian gene therapy platform for both human and animal health. As part of its ongoing GF-1004 Dog Aging study, which has reported no adverse events, these agreements provide a framework for evaluating partnership opportunities aimed at extending healthspan and improving the quality of life in companion animals, a rapidly growing market segment. This collaboration is expected to accelerate the path to commercialization, unlocking global scale and regulatory expertise.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDL4KHpnB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK5083","GENF.UK"],"gpt_icon":0}],"profile":{"websiteUrl":"http://genflowbio.com","stockEarnings":[{"period":"1week","weight":0.0411},{"period":"1month","weight":0.0326},{"period":"3month","weight":1},{"period":"6month","weight":1.6207},{"period":"1year","weight":0.0615},{"period":"ytd","weight":0.0556}],"compareEarnings":[{"period":"1week","weight":0.0084},{"period":"1month","weight":0.0274},{"period":"3month","weight":0.0557},{"period":"6month","weight":0.142},{"period":"1year","weight":0.2482},{"period":"ytd","weight":0.0022}],"compareStock":{"symbol":"ISF.UK","name":"FTSE100 ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.124199},{"month":2,"riseRate":0.25,"avgChangeRate":-0.073492},{"month":3,"riseRate":0.25,"avgChangeRate":-0.20471},{"month":4,"riseRate":0.5,"avgChangeRate":0.437749},{"month":5,"riseRate":0.25,"avgChangeRate":-0.166687},{"month":6,"riseRate":0,"avgChangeRate":-0.196119},{"month":7,"riseRate":0.25,"avgChangeRate":-0.032756},{"month":8,"riseRate":0.75,"avgChangeRate":0.080997},{"month":9,"riseRate":0.25,"avgChangeRate":0.072577},{"month":10,"riseRate":0.25,"avgChangeRate":0.00041},{"month":11,"riseRate":0.5,"avgChangeRate":0.171701},{"month":12,"riseRate":0.5,"avgChangeRate":-0.071003}],"exchange":"LSE","name":"GENFLOW BIOSCIENCES PLC","nameEN":"GENFLOW BIOSCIENCES PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"GENFLOW BIOSCIENCES PLC(GENF.UK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest GENFLOW BIOSCIENCES PLC(GENF.UK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"GENFLOW BIOSCIENCES PLC,GENF.UK,GENFLOW BIOSCIENCES PLC股票,GENFLOW BIOSCIENCES PLC股票老虎,GENFLOW BIOSCIENCES PLC股票老虎国际,GENFLOW BIOSCIENCES PLC行情,GENFLOW BIOSCIENCES PLC股票行情,GENFLOW BIOSCIENCES PLC股价,GENFLOW BIOSCIENCES PLC股市,GENFLOW BIOSCIENCES PLC股票价格,GENFLOW BIOSCIENCES PLC股票交易,GENFLOW BIOSCIENCES PLC股票购买,GENFLOW BIOSCIENCES PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"GENFLOW BIOSCIENCES PLC(GENF.UK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest GENFLOW BIOSCIENCES PLC(GENF.UK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction